{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:47:15Z","timestamp":1792014435124,"version":"4.4.0"},"reference-count":236,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Depression is one of the most common and disabling neuropsychiatric complications of neurodegenerative diseases. In Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD), depressive syndromes affect more than one-third of patients and are associated with accelerated cognitive decline, reduced quality of life, and increased healthcare utilisation. Despite this burden, current antidepressant treatments show little or no efficacy in these populations, suggesting that depression arising in the context of neurodegeneration may reflect distinct underlying neurobiological mechanisms. Emerging evidence from molecular imaging, neuropathology, and cognitive neuroscience indicates disease-specific disruption of monoaminergic, glutamatergic, inflammatory, and reward-related circuits in AD and PD. These alterations may undermine the mechanisms of action of standard antidepressants and contribute to treatment resistance. Yet patients with cognitive impairment are routinely excluded from antidepressant trials, and few high-quality studies have evaluated novel therapies in neurodegenerative disease. In this narrative review, we synthesise current evidence on the neurobiological mechanisms underpinning depression in AD and PD and critically evaluate emerging pharmacological and neuromodulatory therapies targeting glutamatergic, serotonergic, dopaminergic, immune, and circuit-level dysfunction. Here, we highlight that depression in neurodegenerative disease offers a unique and underutilised model for mechanistically guided antidepressant development. We identify how interventions including glutamate modulators, dopaminergic agents, kappa opioid antagonists, immune-modulating therapies, and next-generation brain stimulation approaches may offer therapeutic promise. By aligning treatment development with disease-specific circuit and molecular pathology, this framework may improve outcomes for this neglected population while advancing precision psychiatry more broadly.<\/jats:p>","DOI":"10.1038\/s41380-026-03728-8","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:29:22Z","timestamp":1783340962000},"page":"6603-6621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-9219","authenticated-orcid":false,"given":"Harry","family":"Costello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"3728_CR1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"Q-F Zhao","year":"2016","unstructured":"Zhao Q-F, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264\u201371.","journal-title":"J Affect Disord"},{"key":"3728_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JSAM Reijnders","year":"2008","unstructured":"Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord. 2008;23:183\u20139.","journal-title":"Mov Disord"},{"key":"3728_CR3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3233\/JAD-140405","volume":"42","author":"S Van der Mussele","year":"2014","unstructured":"Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Mari\u00ebn P, Saerens J, et al. Depression in mild cognitive impairment is associated with progression to Alzheimer\u2019s disease: a longitudinal study. J Alzheimer\u2019s Dis. 2014;42:1239\u201350.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3728_CR4","doi-asserted-by":"crossref","first-page":"100870","DOI":"10.1016\/j.lanepe.2024.100870","volume":"39","author":"E Burchill","year":"2024","unstructured":"Burchill E, Watson CJ, Fanshawe JB, Badenoch JB, Rengasamy E, Ghanem DA, et al. The impact of psychiatric comorbidity on Parkinson\u2019s disease outcomes: a systematic review and meta-analysis. Lancet Reg Health Eur. 2024;39:100870.","journal-title":"Lancet Reg Health Eur"},{"key":"3728_CR5","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1468-1331.2010.02984.x","volume":"17","author":"Y Winter","year":"2010","unstructured":"Winter Y, Balzer-Geldsetzer M, Spottke A, Reese JP, Baum E, Klotsche J, et al. Longitudinal study of the socioeconomic burden of Parkinson\u2019s disease in Germany. Eur J Neurol. 2010;17:1156\u201363.","journal-title":"Eur J Neurol"},{"key":"3728_CR6","doi-asserted-by":"crossref","first-page":"e013591","DOI":"10.1136\/bmjopen-2016-013591","volume":"6","author":"M Knapp","year":"2016","unstructured":"Knapp M, Chua K-C, Broadbent M, Chang C-K, Fernandez J-L, Milea D, et al. Predictors of care home and hospital admissions and their costs for older people with Alzheimer\u2019s disease: findings from a large London case register. BMJ Open. 2016;6:e013591.","journal-title":"BMJ Open"},{"key":"3728_CR7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1212\/01.WNL.0000036904.73393.E4","volume":"59","author":"DL Murman","year":"2002","unstructured":"Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002;59:1721\u20139.","journal-title":"Neurology"},{"key":"3728_CR8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-190426","volume":"70","author":"YH El-Hayek","year":"2019","unstructured":"El-Hayek YH, Wiley RE, Khoury CP, Daya RP, Ballard C, Evans AR, et al. Tip of the iceberg: assessing the global socioeconomic costs of Alzheimer\u2019s disease and related dementias and strategic implications for stakeholders. J Alzheimer\u2019s Dis. 2019;70:323\u201341.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3728_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-0839-1","volume":"10","author":"FS Dafsari","year":"2020","unstructured":"Dafsari FS, Jessen F. Depression-an underrecognized target for prevention of dementia in Alzheimer\u2019s disease. Transl Psychiatry. 2020;10:160.","journal-title":"Transl Psychiatry"},{"key":"3728_CR10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","volume":"63","author":"RL Ownby","year":"2006","unstructured":"Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"3728_CR11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pnpbp.2018.05.025","volume":"86","author":"S Wang","year":"2018","unstructured":"Wang S, Mao S, Xiang D, Fang C. Association between depression and the subsequent risk of Parkinson\u2019s disease: a meta-analysis. Prog Neuro-psychopharmacol Biol Psychiatry. 2018;86:186\u201392.","journal-title":"Prog Neuro-psychopharmacol Biol Psychiatry"},{"key":"3728_CR12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/JGP.0b013e3181e898d0","volume":"19","author":"MA Rapp","year":"2011","unstructured":"Rapp MA, Schnaider-Beeri M, Wysocki M, Guerrero-Berroa E, Grossman HT, Heinz A, et al. Cognitive decline in patients with dementia as a function of depression. Am J Geriatr Psychiatry. 2011;19:357\u201363.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3728_CR13","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. Lancet. 2024;404:572\u2013628.","journal-title":"Lancet"},{"key":"3728_CR14","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1017\/S003329172200397X","volume":"53","author":"H Costello","year":"2023","unstructured":"Costello H, Roiser JP, Howard R. Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance. Psychol Med. 2023;53:654\u201367.","journal-title":"Psychol Med"},{"key":"3728_CR15","doi-asserted-by":"crossref","first-page":"e79510","DOI":"10.1371\/journal.pone.0079510","volume":"8","author":"L Troeung","year":"2013","unstructured":"Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson\u2019s disease. PLoS One. 2013;8:e79510.","journal-title":"PLoS One"},{"key":"3728_CR16","doi-asserted-by":"crossref","first-page":"e76651","DOI":"10.1371\/journal.pone.0076651","volume":"8","author":"J Liu","year":"2013","unstructured":"Liu J, Dong J, Wang L, Su Y, Yan P, Sun S. Comparative efficacy and acceptability of antidepressants in Parkinson\u2019s disease: a network meta-analysis. PLoS One. 2013;8:e76651.","journal-title":"PLoS One"},{"key":"3728_CR17","doi-asserted-by":"publisher","first-page":"CD003944","DOI":"10.1002\/14651858.CD003944.pub2","volume":"8","author":"R Dudas","year":"2018","unstructured":"Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev. 2018;8:CD003944 https:\/\/doi.org\/10.1002\/14651858.CD003944.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3728_CR18","doi-asserted-by":"crossref","first-page":"116114","DOI":"10.1016\/j.psychres.2024.116114","volume":"340","author":"E Lenouvel","year":"2024","unstructured":"Lenouvel E, Tobias S, M\u00fchlbauer V, Dallmeier D, Denkinger M, Kl\u00f6ppel S, et al. Antidepressants for treating depression among older adults with dementia: a systematic review and meta-analysis. Psychiatry Res. 2024;340:116114.","journal-title":"Psychiatry Res"},{"key":"3728_CR19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1017\/S1041610214002427","volume":"27","author":"M-L Laitinen","year":"2015","unstructured":"Laitinen M-L, L\u00f6nnroos E, Bell JS, Lavikainen P, Sulkava R, Hartikainen S. Use of antidepressants among community-dwelling persons with Alzheimer\u2019s disease: a nationwide register-based study. Int Psychogeriatr. 2015;27:669\u201372.","journal-title":"Int Psychogeriatr"},{"key":"3728_CR20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.parkreldis.2016.04.015","volume":"27","author":"Y Haasum","year":"2016","unstructured":"Haasum Y, Fastbom J, Johnell K. Use of antidepressants in Parkinson\u2019s disease: a Swedish register-based study of over 1.5 million older people. Parkinsonism Relat Disord. 2016;27:85\u201388.","journal-title":"Parkinsonism Relat Disord"},{"key":"3728_CR21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/brain\/awaf098","volume":"148","author":"H Costello","year":"2025","unstructured":"Costello H, Yamamori Y, Kieslich K, Murphy M, Bobyreva K, Schrag A-E, et al. Impaired reward sensitivity in Parkinson\u2019s depression is unresponsive to dopamine treatment. Brain. 2025;148:2122\u201334.","journal-title":"Brain"},{"key":"3728_CR22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jad.2024.06.003","volume":"361","author":"L Xue","year":"2024","unstructured":"Xue L, Bocharova M, Young AH, Aarsland D. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: the role of age at first onset and change in depressive symptoms. J Affect Disord. 2024;361:74\u201381.","journal-title":"J Affect Disord"},{"key":"3728_CR23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/13872877251378156","volume":"108","author":"G Gitlin-Leigh","year":"2025","unstructured":"Gitlin-Leigh G, Wilson J, Howard R, Howard R, Costello H. Effects of monoclonal antibody therapies on depression in Parkinson\u2019s disease and Alzheimer\u2019s disease: systematic review and meta-analysis. J Alzheimers Dis. 2025;108:500\u20138.","journal-title":"J Alzheimers Dis"},{"key":"3728_CR24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"SF Traynelis","year":"2010","unstructured":"Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev. 2010;62:405\u201396.","journal-title":"Pharmacol Rev"},{"key":"3728_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02024-7","volume":"12","author":"H Targa Dias Anastacio","year":"2022","unstructured":"Targa Dias Anastacio H, Matosin N, Ooi L. Neuronal hyperexcitability in Alzheimer\u2019s disease: what are the drivers behind this aberrant phenotype? Transl Psychiatry. 2022;12:257.","journal-title":"Transl Psychiatry"},{"key":"3728_CR26","doi-asserted-by":"crossref","first-page":"e064821","DOI":"10.1002\/alz.064821","volume":"18","author":"C Soares","year":"2022","unstructured":"Soares C, das Ros LU, da Rocha AS, Machado LS, Bellaver B, Zimmer ER. The glutamatergic system in Alzheimer\u2019s disease: a systematic review with meta-analysis. Alzheimer\u2019s Dement. 2022;18:e064821.","journal-title":"Alzheimer\u2019s Dement"},{"key":"3728_CR27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fpsyt.2018.00561","volume":"9","author":"C Madeira","year":"2018","unstructured":"Madeira C, Vargas-Lopes C, Brand\u00e3o CO, Reis T, Laks J, Panizzutti R, et al. Elevated glutamate and glutamine levels in the cerebrospinal fluid of patients with probable Alzheimer\u2019s disease and depression. Front Psychiatry. 2018;9:561.","journal-title":"Front Psychiatry"},{"key":"3728_CR28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci. 2020;144:151\u201364.","journal-title":"J Pharmacol Sci"},{"key":"3728_CR29","doi-asserted-by":"crossref","first-page":"105697","DOI":"10.1016\/j.nbd.2022.105697","volume":"168","author":"F Campanelli","year":"2022","unstructured":"Campanelli F, Natale G, Marino G, Ghiglieri V, Calabresi P. Striatal glutamatergic hyperactivity in Parkinson\u2019s disease. Neurobiol Dis. 2022;168:105697.","journal-title":"Neurobiol Dis"},{"key":"3728_CR30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol. 2021;20:1048\u201356.","journal-title":"Lancet Neurol"},{"key":"3728_CR31","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/brain\/awab373","volume":"145","author":"T Steinkellner","year":"2022","unstructured":"Steinkellner T, Conrad WS, Kovacs I, Rissman RA, Lee EB, Trojanowski JQ, et al. Dopamine neurons exhibit emergent glutamatergic identity in Parkinson\u2019s disease. Brain. 2022;145:879\u201386.","journal-title":"Brain"},{"key":"3728_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","volume":"24","author":"S Moriguchi","year":"2019","unstructured":"Moriguchi S, Takamiya A, Noda Y, Horita N, Wada M, Tsugawa S, et al. Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Mol Psychiatry. 2019;24:952\u201364.","journal-title":"Mol Psychiatry"},{"key":"3728_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrd2462","volume":"7","author":"G Sanacora","year":"2008","unstructured":"Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"3728_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16:472\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"3728_CR35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","volume":"102","author":"RS Duman","year":"2019","unstructured":"Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102:75\u201390.","journal-title":"Neuron"},{"key":"3728_CR36","doi-asserted-by":"crossref","unstructured":"McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154.","DOI":"10.1002\/14651858.CD003154.pub6"},{"key":"3728_CR37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jad.2022.03.047","volume":"306","author":"T-W Hsu","year":"2022","unstructured":"Hsu T-W, Chu C-S, Ching P-Y, Chen G-W, Pan C-C. The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-analysis of double-blind randomized controlled trials. J Affect Disord. 2022;306:182\u20139.","journal-title":"J Affect Disord"},{"key":"3728_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"3728_CR39","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"3728_CR40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","volume":"151","author":"Y Alnefeesi","year":"2022","unstructured":"Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693\u2013709.","journal-title":"J Psychiatr Res"},{"key":"3728_CR41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"3728_CR42","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","volume":"277","author":"WS Marcantoni","year":"2020","unstructured":"Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: january 2009 \u2013 january 2019. J Affect Disord. 2020;277:831\u201341.","journal-title":"J Affect Disord"},{"key":"3728_CR43","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00213-021-05825-8","volume":"238","author":"AA Conley","year":"2021","unstructured":"Conley AA, Norwood AEQ, Hatvany TC, Griffith JD, Barber KE. Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: a meta-analysis. Psychopharmacology. 2021;238:1737\u201352.","journal-title":"Psychopharmacology"},{"key":"3728_CR44","doi-asserted-by":"crossref","first-page":"102127","DOI":"10.1016\/j.eclinm.2023.102127","volume":"62","author":"S Nikolin","year":"2023","unstructured":"Nikolin S, Rodgers A, Schwaab A, Bahji A, Zarate C, Vazquez G, et al. Ketamine for the treatment of major depression: a systematic review and meta-analysis. EClinicalMedicine. 2023;62:102127.","journal-title":"EClinicalMedicine"},{"key":"3728_CR45","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41386-024-02044-5","volume":"50","author":"J Saelens","year":"2024","unstructured":"Saelens J, Gramser A, Watzal V, Zarate CA, Lanzenberger R, Kraus C. Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials. Neuropsychopharmacol. 2024;50:913\u20139.","journal-title":"Neuropsychopharmacol"},{"key":"3728_CR46","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jagp.2023.06.016","volume":"31","author":"G d\u2019Andrea","year":"2023","unstructured":"d\u2019Andrea G, Chiappini S, McIntyre RS, Stefanelli G, Carullo R, Andriola I, et al. Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): a post-hoc analysis from the REAL-ESK study group. Am J Geriatr Psychiatry. 2023;31:1032\u201341.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3728_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0624-1","volume":"9","author":"C Yang","year":"2019","unstructured":"Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry. 2019;9:280.","journal-title":"Transl Psychiatry"},{"key":"3728_CR48","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23:801\u201311.","journal-title":"Mol Psychiatry"},{"key":"3728_CR49","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","volume":"276","author":"RS McIntyre","year":"2020","unstructured":"McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H, et al. The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis. J Affect Disord. 2020;276:576\u201384.","journal-title":"J Affect Disord"},{"key":"3728_CR50","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/s41591-024-03063-x","volume":"30","author":"P Glue","year":"2024","unstructured":"Glue P, Loo C, Fam J, Lane H-Y, Young AH, Surman P. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024;30:2004\u20139.","journal-title":"Nat Med"},{"key":"3728_CR51","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959\u201364.","journal-title":"Science"},{"key":"3728_CR52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/03009734.2012.724118","volume":"118","author":"C Yang","year":"2013","unstructured":"Yang C, Hu Y-M, Zhou Z-Q, Zhang G-F, Yang J-J. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci. 2013;118:3\u20138.","journal-title":"Ups J Med Sci"},{"key":"3728_CR53","doi-asserted-by":"crossref","first-page":"eaat8078","DOI":"10.1126\/science.aat8078","volume":"364","author":"RN Moda-Sava","year":"2019","unstructured":"Moda-Sava RN, Murdock MH, Parekh PK, Fetcho RN, Huang BS, Huynh TN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.","journal-title":"Science"},{"key":"3728_CR54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/ijms20020257","volume":"20","author":"TKS Ng","year":"2019","unstructured":"Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC-M. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer\u2019s disease (AD): a systematic review and meta-analysis. Int J Mol Sci. 2019;20:257.","journal-title":"Int J Mol Sci"},{"key":"3728_CR55","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3233\/JAD-2009-1191","volume":"18","author":"B Borroni","year":"2009","unstructured":"Borroni B, Grassi M, Archetti S, Costanzi C, Bianchi M, Caimi L, et al. BDNF genetic variations increase the risk of Alzheimer\u2019s disease-related depression. J Alzheimer\u2019s Dis. 2009;18:867\u201375.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3728_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.105","volume":"4","author":"N Lally","year":"2014","unstructured":"Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469.","journal-title":"Transl Psychiatry"},{"key":"3728_CR57","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00213-022-06105-9","volume":"239","author":"D Nogo","year":"2022","unstructured":"Nogo D, Jasrai AK, Kim H, Nasri F, Ceban F, Lui LMW, et al. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits. Psychopharmacology. 2022;239:2011\u201339.","journal-title":"Psychopharmacology"},{"key":"3728_CR58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jad.2020.09.056","volume":"278","author":"RS Delfino","year":"2021","unstructured":"Delfino RS, Del-Porto JA, Surjan J, Magalh\u00e3es E, Sant LCD, Lucchese AC, et al. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression. J Affect Disord. 2021;278:515\u20138.","journal-title":"J Affect Disord"},{"key":"3728_CR59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0033291711001905","volume":"42","author":"R Uher","year":"2012","unstructured":"Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2012;42:967\u201380.","journal-title":"Psychol Med"},{"key":"3728_CR60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/HRP.0000000000000312","volume":"29","author":"B Souza-Marques","year":"2021","unstructured":"Souza-Marques B, Santos-Lima C, Ara\u00fajo-de-Freitas L, Vieira F, Jesus-Nunes AP, Quarantini LC, et al. Neurocognitive effects of ketamine and esketamine for treatment-resistant major depressive disorder: a systematic review. Harv Rev Psychiatry. 2021;29:340.","journal-title":"Harv Rev Psychiatry"},{"key":"3728_CR61","unstructured":"Ketamine-induced hippocampal functional connectivity alterations associated with clinical remission in major depression - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/36646174\/. Accessed 30 January 2025."},{"key":"3728_CR62","unstructured":"Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32871692\/. Accessed 30 January 2025."},{"key":"3728_CR63","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1176\/jnp.15.3.346","volume":"15","author":"OL Lopez","year":"2003","unstructured":"Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci. 2003;15:346\u201353.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3728_CR64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-pharmtox-022423-014645","volume":"64","author":"H Costello","year":"2024","unstructured":"Costello H, Husain M, Roiser JP. Apathy and motivation: biological basis and drug treatment. Annu Rev Pharmacol Toxicol. 2024;64:313\u201338.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3728_CR65","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41380-020-00878-1","volume":"26","author":"A Mkrtchian","year":"2021","unstructured":"Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, et al. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. 2021;26:3292\u2013301.","journal-title":"Mol Psychiatry"},{"key":"3728_CR66","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0269881114568041","volume":"29","author":"N Lally","year":"2015","unstructured":"Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29:596\u2013607.","journal-title":"J Psychopharmacol"},{"key":"3728_CR67","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314:1242\u201354.","journal-title":"JAMA"},{"key":"3728_CR68","first-page":"21m14345","volume":"83","author":"DV Iosifescu","year":"2022","unstructured":"Iosifescu DV, Jones A, O\u2019Gorman C, Streicher C, Feliz S, Fava M, et al. Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022;83:21m14345.","journal-title":"J Clin Psychiatry"},{"key":"3728_CR69","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693\u2013702.","journal-title":"Ann Neurol"},{"key":"3728_CR70","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00406-023-01571-4","volume":"273","author":"M Fava","year":"2023","unstructured":"Fava M, Stahl SM, De Martin S, Mattarei A, Bettini E, Comai S, et al. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci. 2023;273:1463\u201376.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3728_CR71","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","volume":"179","author":"M Fava","year":"2022","unstructured":"Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, et al. REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry. 2022;179:122\u201331.","journal-title":"Am J Psychiatry"},{"key":"3728_CR72","first-page":"24m15748","volume":"86","author":"C Guidetti","year":"2025","unstructured":"Guidetti C, Papakostas GI, Pani L, De Martin S, Serra G, Apicella M, et al. Esmethadone (REL-1017) in patients with major depressive disorder and antidepressant tachyphylaxis: an exploratory post hoc analysis from a phase 3 randomized controlled trial. J Clin Psychiatry. 2025;86:24m15748.","journal-title":"J Clin Psychiatry"},{"key":"3728_CR73","doi-asserted-by":"crossref","first-page":"671859","DOI":"10.3389\/fphar.2021.671859","volume":"12","author":"S De Martin","year":"2021","unstructured":"De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, et al. REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study. Front Pharmacol. 2021;12:671859.","journal-title":"Front Pharmacol"},{"key":"3728_CR74","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.0305-1846.2000.00291.x","volume":"26","author":"U R\u00fcb","year":"2000","unstructured":"R\u00fcb U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. The evolution of Alzheimer\u2019s disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol. 2000;26:553\u201367.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3728_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0197-4580(02)00057-X","volume":"24","author":"SA Lyness","year":"2003","unstructured":"Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging. 2003;24:1\u201323.","journal-title":"Neurobiol Aging"},{"key":"3728_CR76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nbd.2017.05.007","volume":"105","author":"GS Smith","year":"2017","unstructured":"Smith GS, Barrett FS, Joo JH, Nassery N, Savonenko A, Sodums DJ, et al. Molecular imaging of serotonin degeneration in mild cognitive impairment. Neurobiol Dis. 2017;105:33\u201341.","journal-title":"Neurobiol Dis"},{"key":"3728_CR77","doi-asserted-by":"crossref","first-page":"102062","DOI":"10.1016\/j.nicl.2019.102062","volume":"25","author":"JJ van der Zande","year":"2019","unstructured":"van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens PH, Booij J, et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer\u2019s disease pathology: an 123I-FP-CIT SPECT study. Neuroimage Clin. 2019;25:102062.","journal-title":"Neuroimage Clin"},{"key":"3728_CR78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ana.410240210","volume":"24","author":"RM Zweig","year":"1988","unstructured":"Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, et al. The neuropathology of aminergic nuclei in Alzheimer\u2019s disease. Ann Neurol. 1988;24:233\u201342.","journal-title":"Ann Neurol"},{"key":"3728_CR79","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1046\/j.1471-4159.1996.66041592.x","volume":"66","author":"CPL-H Chen","year":"1996","unstructured":"Chen CPL-H, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer\u2019s disease: correlations with depression and neuroleptic medication. J Neurochem. 1996;66:1592\u20138.","journal-title":"J Neurochem"},{"key":"3728_CR80","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.109.063008","volume":"50","author":"Y Ouchi","year":"2009","unstructured":"Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K. Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med. 2009;50:1260\u20136.","journal-title":"J Nucl Med"},{"key":"3728_CR81","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/mds.22212","volume":"23","author":"I Boileau","year":"2008","unstructured":"Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinson\u2019s disease: a preliminary PET study with [11C]DASB. Mov Disord. 2008;23:1776\u201380.","journal-title":"Mov Disord"},{"key":"3728_CR82","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.parkreldis.2019.03.025","volume":"77","author":"J Pasquini","year":"2020","unstructured":"Pasquini J, Ceravolo R, Brooks DJ, Bonuccelli U, Pavese N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson\u2019s disease: a longitudinal 123I-FP-CIT SPECT study. Parkinsonism Relat Disord. 2020;77:170\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"3728_CR83","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/mds.23895","volume":"27","author":"B Ballanger","year":"2012","unstructured":"Ballanger B, Klinger H, Eche J, Lerond J, Vallet A-E, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson\u2019s disease. Mov Disord. 2012;27:84\u201389.","journal-title":"Mov Disord"},{"key":"3728_CR84","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/brain\/awy240","volume":"141","author":"TR Barber","year":"2018","unstructured":"Barber TR, Griffanti L, Muhammed K, Drew DS, Bradley KM, McGowan DR, et al. Apathy in rapid eye movement sleep behaviour disorder s associated with serotonin depletion he dorsal raphe nucleus. Brain. 2018;141:2848\u201354.","journal-title":"Brain"},{"key":"3728_CR85","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(11)60830-1","volume":"378","author":"S Banerjee","year":"2011","unstructured":"Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378:403\u201311.","journal-title":"Lancet"},{"key":"3728_CR86","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","volume":"72","author":"M Menza","year":"2009","unstructured":"Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009;72:886\u201392.","journal-title":"Neurology"},{"key":"3728_CR87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.9758\/cpn.2022.20.2.311","volume":"20","author":"HW Jeong","year":"2022","unstructured":"Jeong HW, Yoon KH, Lee CH, Moon YS, Kim DH. Vortioxetine treatment for depression in Alzheimer\u2019s disease: a randomized, double-blind, placebo-controlled Study. Clin Psychopharmacol Neurosci. 2022;20:311\u20139.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"3728_CR88","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","volume":"35","author":"J Tack","year":"2012","unstructured":"Tack J, Camilleri M, Chang L, Chey WD, Galligan JJ, Lacy BE, et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745\u201367.","journal-title":"Aliment Pharmacol Ther"},{"key":"3728_CR89","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.112.192351","volume":"341","author":"DE Johnson","year":"2012","unstructured":"Johnson DE, Drummond E, Grimwood S, Sawant-Basak A, Miller E, Tseng E, et al. The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal \u03b8 oscillations. J Pharmacol Exp Ther. 2012;341:681\u201391.","journal-title":"J Pharmacol Exp Ther"},{"key":"3728_CR90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuroscience.2004.06.070","volume":"129","author":"JP Spencer","year":"2004","unstructured":"Spencer JP, Brown JT, Richardson JC, Medhurst AD, Sehmi SS, Calver AR, et al. Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer\u2019s disease. Neuroscience. 2004;129:49\u201354.","journal-title":"Neuroscience"},{"key":"3728_CR91","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3565(24)38802-0","volume":"296","author":"M Matsumoto","year":"2001","unstructured":"Matsumoto M, Togashi H, Mori K, Ueno K, Ohashi S, Kojima T, et al. Evidence for involvement of central 5-HT4 receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther. 2001;296:676\u201382.","journal-title":"J Pharmacol Exp Ther"},{"key":"3728_CR92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2011.02.026","volume":"61","author":"F Shen","year":"2011","unstructured":"Shen F, Smith JAM, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP, et al. 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61:69\u201379.","journal-title":"Neuropharmacology"},{"key":"3728_CR93","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.neurobiolaging.2013.01.020","volume":"34","author":"I Tesseur","year":"2013","unstructured":"Tesseur I, Pimenova AA, Lo AC, Ciesielska M, Lichtenthaler SF, De Maeyer JH, et al. Chronic 5-HT4 receptor activation decreases A\u03b2 production and deposition in hAPP\/PS1 mice. Neurobiol Aging. 2013;34:1779\u201389.","journal-title":"Neurobiol Aging"},{"key":"3728_CR94","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fnagi.2013.00096","volume":"5","author":"P Giannoni","year":"2013","unstructured":"Giannoni P, Gaven F, de Bundel D, Baranger K, Marchetti-Gauthier E, Roman FS, et al. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer\u2019s disease. Front Aging Neurosci. 2013;5:96.","journal-title":"Front Aging Neurosci"},{"key":"3728_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01568-4","volume":"11","author":"AN de Cates","year":"2021","unstructured":"de Cates AN, Wright LC, Martens MAG, Gibson D, T\u00fcrkmen C, Filippini N, et al. D\u00e9j\u00e0-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task. Transl Psychiatry. 2021;11:497.","journal-title":"Transl Psychiatry"},{"key":"3728_CR96","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1017\/S0033291719002836","volume":"50","author":"SE Murphy","year":"2020","unstructured":"Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ. A role for 5-HT4 receptors in human learning and memory. Psychol Med. 2020;50:2722\u201330.","journal-title":"Psychol Med"},{"key":"3728_CR97","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1002\/hbm.22123","volume":"34","author":"ME Haahr","year":"2013","unstructured":"Haahr ME, Fisher P, Holst K, Madsen K, Jensen CG, Marner L, et al. The 5-HT4 receptor levels in hippocampus correlates inversely with memory test performance in humans. Hum Brain Mapp. 2013;34:3066\u201374.","journal-title":"Hum Brain Mapp"},{"key":"3728_CR98","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.2024.97","volume":"225","author":"AN de Cates","year":"2024","unstructured":"de Cates AN, Harmer CJ, Harrison PJ, Cowen PJ, Emmanuel A, Travis S, et al. Association between a selective 5-HT4 agonist and incidence of major depressive disorder: an emulated target trial. Br J Psychiatry. 2024;225:371\u20138.","journal-title":"Br J Psychiatry"},{"key":"3728_CR99","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/ene.13082","volume":"23","author":"P Stirpe","year":"2016","unstructured":"Stirpe P, Hoffman M, Badiali D, Colosimo C. Constipation: an emerging risk factor for Parkinson\u2019s disease? Eur J Neurol. 2016;23:1606\u201313.","journal-title":"Eur J Neurol"},{"key":"3728_CR100","doi-asserted-by":"crossref","first-page":"102371","DOI":"10.1016\/j.eclinm.2023.102371","volume":"67","author":"Q Yun","year":"2024","unstructured":"Yun Q, Wang S, Chen S, Luo H, Li B, Yip P, et al. Constipation preceding depression: a population-based cohort study. EClinicalMedicine. 2024;67:102371.","journal-title":"EClinicalMedicine"},{"key":"3728_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72381-0","volume":"10","author":"T-Y Chang","year":"2020","unstructured":"Chang T-Y, Chen Y-H, Chang M-H, Lin C-H. Is there a close association of depression with either constipation or dysosmia in Parkinson\u2019s disease? Sci Rep. 2020;10:15476.","journal-title":"Sci Rep"},{"key":"3728_CR102","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","volume":"78","author":"D Nutt","year":"2021","unstructured":"Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. JAMA Psychiatry. 2021;78:121\u20132.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR103","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"3728_CR104","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"3728_CR105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49:655\u201363.","journal-title":"Psychol Med"},{"key":"3728_CR106","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacol. 2022;47:1854\u201362.","journal-title":"Neuropsychopharmacol"},{"key":"3728_CR107","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","volume":"28","author":"RE Daws","year":"2022","unstructured":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28:844\u201351.","journal-title":"Nat Med"},{"key":"3728_CR108","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tics.2023.01.003","volume":"27","author":"M Girn","year":"2023","unstructured":"Girn M, Rosas FE, Daws RE, Gallen CL, Gazzaley A, Carhart-Harris RL. A complex systems perspective on psychedelic brain action. Trends Cognit Sci. 2023;27:433\u201345.","journal-title":"Trends Cognit Sci"},{"key":"3728_CR109","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","volume":"25","author":"P Huot","year":"2010","unstructured":"Huot P, Johnston TH, Darr T, Hazrati L-N, Visanji NP, Pires D, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord. 2010;25:1399\u2013408.","journal-title":"Mov Disord"},{"key":"3728_CR110","first-page":"5320135","volume":"2017","author":"L Tang","year":"2017","unstructured":"Tang L, Wang Y, Chen Y, Chen L, Zheng S, Bao M, et al. The association between 5HT2A T102C and behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease: a meta-analysis. BioMed Res Int. 2017;2017:5320135.","journal-title":"BioMed Res Int"},{"key":"3728_CR111","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/02698811241246857","volume":"38","author":"JJ Rucker","year":"2024","unstructured":"Rucker JJ, Roberts C, Seynaeve M, Young AH, Suttle B, Yamamoto T, et al. Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol. 2024;38:712\u201323.","journal-title":"J Psychopharmacol"},{"key":"3728_CR112","first-page":"46","volume":"19","author":"Z Mansuri","year":"2022","unstructured":"Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A. Pimavanserin in the treatment of Parkinson\u2019s disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci. 2022;19:46\u201351.","journal-title":"Innov Clin Neurosci"},{"key":"3728_CR113","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.euroneuro.2013.04.013","volume":"25","author":"F Artigas","year":"2015","unstructured":"Artigas F. Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol. 2015;25:657\u201370.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3728_CR114","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fpsyg.2019.00691","volume":"10","author":"SA Langenecker","year":"2019","unstructured":"Langenecker SA, Mickey BJ, Eichhammer P, Sen S, Elverman KH, Kennedy SE, et al. Cognitive control as a 5-HT1A-based domain that is disrupted in major depressive disorder. Front Psychol. 2019;10:691.","journal-title":"Front Psychol"},{"key":"3728_CR115","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.euroneuro.2015.04.017","volume":"25","author":"V Pittal\u00e0","year":"2015","unstructured":"Pittal\u00e0 V, Siracusa MA, Salerno L, Romeo G, Modica MN, Madjid N, et al. Analysis of mechanisms for memory enhancement using novel and potent 5-HT1A receptor ligands. Eur Neuropsychopharmacol. 2015;25:1314\u201323.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3728_CR116","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","volume":"974","author":"MKP Lai","year":"2003","unstructured":"Lai MKP, Tsang SWY, Francis PT, Esiri MM, Keene J, Hope T, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974:82\u201387.","journal-title":"Brain Res"},{"key":"3728_CR117","first-page":"19m12928","volume":"80","author":"M Fava","year":"2019","unstructured":"Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, et al. A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY). J Clin Psychiatry. 2019;80:19m12928.","journal-title":"J Clin Psychiatry"},{"key":"3728_CR118","doi-asserted-by":"crossref","first-page":"8","DOI":"10.64719\/pb.4448","volume":"52","author":"B Dirks","year":"2022","unstructured":"Dirks B, Fava M, Atkinson SD, Joyce M, Thase ME, Howell B, et al. Adjunctive pimavanserin in patients with major depressive disorder: combined results from two randomized, double-blind, placebo-controlled phase 3 studies. Psychopharmacol Bull. 2022;52:8\u201330.","journal-title":"Psychopharmacol Bull"},{"key":"3728_CR119","doi-asserted-by":"publisher","first-page":"7188","DOI":"10.1038\/s41380-021-01194-y","volume":"26","author":"C Korn","year":"2021","unstructured":"Korn C, Akam T, Jensen KHR, Vagnoni C, Huber A, Tunbridge EM, et al. Distinct roles for dopamine clearance mechanisms in regulating behavioral flexibility. Mol Psychiatry. 2021;26:7188\u201399.","journal-title":"Mol Psychiatry"},{"key":"3728_CR120","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.275.5306.1593","volume":"275","author":"W Schultz","year":"1997","unstructured":"Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593\u20139.","journal-title":"Science"},{"key":"3728_CR121","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nn.4239","volume":"19","author":"N Eshel","year":"2016","unstructured":"Eshel N, Tian J, Bukwich M, Uchida N. Dopamine neurons share common response function for reward prediction error. Nat Neurosci. 2016;19:479\u201386.","journal-title":"Nat Neurosci"},{"key":"3728_CR122","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41583-018-0029-9","volume":"19","author":"M Husain","year":"2018","unstructured":"Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018;19:470\u201384.","journal-title":"Nat Rev Neurosci"},{"key":"3728_CR123","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","volume":"136","author":"S Thobois","year":"2013","unstructured":"Thobois S, Lhomm\u00e9e E, Klinger H, Ardouin C, Schmitt E, Bichon A, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain. 2013;136:1568\u201377.","journal-title":"Brain"},{"key":"3728_CR124","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.27465","volume":"33","author":"RMJ van der Velden","year":"2018","unstructured":"van der Velden RMJ, Broen MPG, Kuijf ML, Leentjens AFG. Frequency of mood and anxiety fluctuations in Parkinson\u2019s disease patients with motor fluctuations: a systematic review. Mov Disord. 2018;33:1521\u20137.","journal-title":"Mov Disord"},{"key":"3728_CR125","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/jnnp-2022-330790","volume":"94","author":"H Costello","year":"2023","unstructured":"Costello H, Yamamori Y, Reeves S, Schrag A-E, Howard R, Roiser JP. Longitudinal decline in striatal dopamine transporter binding in Parkinson\u2019s disease: associations with apathy and anhedonia. J Neurol Neurosurg Psychiatry. 2023;94:863\u201370. https:\/\/doi.org\/10.1136\/jnnp-2022-330790","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3728_CR126","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/s44220-024-00256-8","volume":"2","author":"H Costello","year":"2024","unstructured":"Costello H, Schrag A-E, Howard R, Roiser JP. Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease. Nat Ment Health. 2024;2:916\u201323.","journal-title":"Nat Ment Health"},{"key":"3728_CR127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jagp.2020.04.026","volume":"29","author":"CH van Dyck","year":"2021","unstructured":"van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, et al. Neurobiologic rationale for treatment of apathy in Alzheimer\u2019s disease with methylphenidate. Am J Geriatr Psychiatry. 2021;29:51\u201362.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3728_CR128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573\u201380.","journal-title":"Lancet Neurol"},{"key":"3728_CR129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/acps.13055","volume":"140","author":"A Tundo","year":"2019","unstructured":"Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr Scand. 2019;140:116\u201325.","journal-title":"Acta Psychiatr Scand"},{"key":"3728_CR130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ebmental-2021-300282","volume":"25","author":"SK Au-Yeung","year":"2022","unstructured":"Au-Yeung SK, Griffiths J, Roberts S, Edwards C, Yu L-M, Bogacz R, et al. PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. Evid Based Ment Health. 2022;25:77\u201383.","journal-title":"Evid Based Ment Health"},{"key":"3728_CR131","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/02698811241309622","volume":"39","author":"RH McAllister-Williams","year":"2025","unstructured":"McAllister-Williams RH, Goudie N, Azim L, Bartle V, Berger M, Butcher C, et al. A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study). J Psychopharmacol. 2025;39:106\u201320.","journal-title":"J Psychopharmacol"},{"key":"3728_CR132","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S2215-0366(25)00194-4","volume":"12","author":"M Browning","year":"2025","unstructured":"Browning M, Cowen PJ, Galal U, Baldwin A, Cleare AJ, Evans J, et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry. 2025;12:579\u201389.","journal-title":"Lancet Psychiatry"},{"key":"3728_CR133","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","volume":"63","author":"J-M Beaulieu","year":"2011","unstructured":"Beaulieu J-M, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011;63:182\u2013217.","journal-title":"Pharmacol Rev"},{"key":"3728_CR134","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biopsych.2023.05.023","volume":"95","author":"DC Halahakoon","year":"2024","unstructured":"Halahakoon DC, Kaltenboeck A, Martens M, Geddes JG, Harmer CJ, Cowen P, et al. Pramipexole enhances reward learning by preserving value estimates. Biol Psychiatry. 2024;95:286\u201396.","journal-title":"Biol Psychiatry"},{"key":"3728_CR135","doi-asserted-by":"crossref","unstructured":"Mkrtchian A, Qiu Z, Abir Y, Erdmann T, Dercon Q, Sedlinska T, et al. Differential associations of dopamine and serotonin with reward and punishment processes in humans: a systematic review and meta-analysis. JAMA Psychiatry. 2025;82:818\u201329.","DOI":"10.1001\/jamapsychiatry.2025.0839"},{"key":"3728_CR136","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1001\/jamaneurol.2021.3356","volume":"78","author":"J Mintzer","year":"2021","unstructured":"Mintzer J, Lanct\u00f4t KL, Scherer RW, Rosenberg PB, Herrmann N, van Dyck CH, et al. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol. 2021;78:1324\u201332.","journal-title":"JAMA Neurol"},{"key":"3728_CR137","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1474-4422(17)30044-3","volume":"16","author":"KA Vossel","year":"2017","unstructured":"Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer\u2019s disease: causes and clinical relevance. Lancet Neurol. 2017;16:311\u201322.","journal-title":"Lancet Neurol"},{"key":"3728_CR138","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ana.25157","volume":"83","author":"K Gruntz","year":"2018","unstructured":"Gruntz K, Bloechliger M, Becker C, Jick SS, Fuhr P, Meier CR, et al. Parkinson disease and the risk of epileptic seizures. Ann Neurol. 2018;83:363\u201374.","journal-title":"Ann Neurol"},{"key":"3728_CR139","doi-asserted-by":"crossref","first-page":"e6013","DOI":"10.1002\/gps.6013","volume":"38","author":"W-C Yeh","year":"2023","unstructured":"Yeh W-C, Hsu C-Y, Li K-Y, Chien C-F, Huang L-C, Yang Y-H. Association between subclinical epileptiform discharge and the behavioral and psychological symptoms in patients with Alzheimer\u2019s dementia. Int J Geriatr Psychiatry. 2023;38:e6013.","journal-title":"Int J Geriatr Psychiatry"},{"key":"3728_CR140","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.biopsych.2014.12.011","volume":"77","author":"AA Fingelkurts","year":"2015","unstructured":"Fingelkurts AA, Fingelkurts AA. Altered structure of dynamic electroencephalogram oscillatory pattern in major depression. Biol Psychiatry. 2015;77:1050\u201360.","journal-title":"Biol Psychiatry"},{"key":"3728_CR141","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1550059415621435","volume":"48","author":"M Arns","year":"2017","unstructured":"Arns M, Gordon E, Boutros NN. EEG abnormalities are associated with poorer depressive symptom outcomes with escitalopram and Venlafaxine-XR, but not sertraline: results from the multicenter randomized iSPOT-D study. Clin EEG Neurosci. 2017;48:33\u201340.","journal-title":"Clin EEG Neurosci"},{"key":"3728_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11671","volume":"7","author":"AK Friedman","year":"2016","unstructured":"Friedman AK, Juarez B, Ku SM, Zhang H, Calizo RC, Walsh JJ, et al. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nat Commun. 2016;7:11671.","journal-title":"Nat Commun"},{"key":"3728_CR143","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","volume":"78","author":"BJ Wainger","year":"2021","unstructured":"Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186\u201396.","journal-title":"JAMA Neurol"},{"key":"3728_CR144","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41380-018-0283-2","volume":"25","author":"A Tan","year":"2020","unstructured":"Tan A, Costi S, Morris LS, Van Dam NT, Kautz M, Whitton AE, et al. Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Mol Psychiatry. 2020;25:1323\u201333.","journal-title":"Mol Psychiatry"},{"key":"3728_CR145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/appi.ajp.2020.20050653","volume":"178","author":"S Costi","year":"2021","unstructured":"Costi S, Morris LS, Kirkwood KA, Hoch M, Corniquel M, Vo-Le B, et al. Impact of the KCNQ2\/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial. Am J Psychiatry. 2021;178:437\u201346.","journal-title":"Am J Psychiatry"},{"key":"3728_CR146","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/jnnp-2021-327762","volume":"93","author":"H Costello","year":"2022","unstructured":"Costello H, Berry AJ, Reeves S, Weil RS, Joyce EM, Howard R, et al. Disrupted reward processing in Parkinson\u2019s disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2022;93:555\u201362. https:\/\/doi.org\/10.1136\/jnnp-2021-327762","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3728_CR147","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/jcbfm.2014.150","volume":"34","author":"M Naganawa","year":"2014","unstructured":"Naganawa M, Zheng M-Q, Nabulsi N, Tomasi G, Henry S, Lin S-F, et al. Kinetic modeling of (11)C-LY2795050, a novel antagonist radiotracer for PET imaging of the kappa opioid receptor in humans. J Cereb Blood Flow Metab. 2014;34:1818\u201325.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3728_CR148","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41386-024-01862-x","volume":"49","author":"ME Schmidt","year":"2024","unstructured":"Schmidt ME, Kezic I, Popova V, Melkote R, Van Der Ark P, Pemberton DJ, et al. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI\/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. Neuropsychopharmacol. 2024;49:1437\u201347.","journal-title":"Neuropsychopharmacol"},{"key":"3728_CR149","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jad.2024.07.030","volume":"362","author":"S Wong","year":"2024","unstructured":"Wong S, Le GH, Vasudeva S, Teopiz KM, Phan L, Meshkat S, et al. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: a systematic review. J Affect Disord. 2024;362:816\u201327.","journal-title":"J Affect Disord"},{"key":"3728_CR150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neuropharm.2013.09.021","volume":"77","author":"LM Rorick-Kehn","year":"2014","unstructured":"Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014;77:131\u201344.","journal-title":"Neuropharmacology"},{"key":"3728_CR151","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.pnpbp.2018.06.001","volume":"86","author":"AV Williams","year":"2018","unstructured":"Williams AV, Laman-Maharg A, Armstrong CV, Ramos-Maciel S, Minie VA, Trainor BC. Acute inhibition of kappa opioid receptors before stress blocks depression-like behaviors in California mice. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:166\u201374.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3728_CR152","doi-asserted-by":"crossref","first-page":"837671","DOI":"10.3389\/fphar.2022.837671","volume":"13","author":"ML Dalefield","year":"2022","unstructured":"Dalefield ML, Scouller B, Bibi R, Kivell BM. The kappa opioid receptor: a promising therapeutic target for multiple pathologies. Front Pharmacol. 2022;13:837671.","journal-title":"Front Pharmacol"},{"key":"3728_CR153","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0006-8993(00)03302-3","volume":"893","author":"AM Mathieu-Kia","year":"2001","unstructured":"Mathieu-Kia AM, Fan LQ, Kreek MJ, Simon EJ, Hiller JM. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer\u2019s disease patients. Brain Res. 2001;893:121\u201334.","journal-title":"Brain Res"},{"key":"3728_CR154","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neulet.2015.08.027","volume":"606","author":"H Ji","year":"2015","unstructured":"Ji H, Wang Y, Liu G, Xu X, Dai D, Chen Z, et al. OPRK1 promoter hypermethylation increases the risk of Alzheimer\u2019s disease. Neurosci Lett. 2015;606:24\u201329.","journal-title":"Neurosci Lett"},{"key":"3728_CR155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2020.03.089","volume":"271","author":"A Dinoff","year":"2020","unstructured":"Dinoff A, Lynch ST, Sekhri N, Klepacz L. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression. J Affect Disord. 2020;271:91\u201399.","journal-title":"J Affect Disord"},{"key":"3728_CR156","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14728214.2024.2345645","volume":"29","author":"E Hampsey","year":"2024","unstructured":"Hampsey E, Jelen L, Young AH. Aticaprant: (a \u03ba-opioid receptor antagonist) for major depressive disorder. Expert Opin Emerg Drugs. 2024;29:193\u2013204.","journal-title":"Expert Opin Emerg Drugs"},{"key":"3728_CR157","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bpa.12785","volume":"30","author":"E Sanchez-Mejias","year":"2020","unstructured":"Sanchez-Mejias E, Nu\u00f1ez-Diaz C, Sanchez-Varo R, Gomez-Arboledas A, Garcia-Leon JA, Fernandez-Valenzuela JJ, et al. Distinct disease-sensitive GABAergic neurons in the perirhinal cortex of Alzheimer\u2019s mice and patients. Brain Pathol. 2020;30:345\u201363.","journal-title":"Brain Pathol"},{"key":"3728_CR158","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuroscience.2021.06.037","volume":"470","author":"W Zhang","year":"2021","unstructured":"Zhang W, Xiong B-R, Zhang L-Q, Huang X, Yuan X, Tian Y-K, et al. The role of the GABAergic system in diseases of the central nervous system. Neuroscience. 2021;470:88\u201399.","journal-title":"Neuroscience"},{"key":"3728_CR159","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41380-020-0727-3","volume":"26","author":"T Pr\u00e9vot","year":"2021","unstructured":"Pr\u00e9vot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26:151\u201367.","journal-title":"Mol Psychiatry"},{"key":"3728_CR160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpsychires.2018.08.015","volume":"105","author":"KEM Godfrey","year":"2018","unstructured":"Godfrey KEM, Gardner AC, Kwon S, Chea W, Muthukumaraswamy SD. Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis. J Psychiatr Res. 2018;105:33\u201344.","journal-title":"J Psychiatr Res"},{"key":"3728_CR161","doi-asserted-by":"crossref","unstructured":"Furukawa TA, Streiner D, Young LT, Kinoshita Y Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev. 2001;2:CD001026.","DOI":"10.1002\/14651858.CD001026"},{"key":"3728_CR162","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.euroneuro.2015.08.014","volume":"25","author":"P Jennum","year":"2015","unstructured":"Jennum P, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol. 2015;25:1906\u201313.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3728_CR163","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jad.2022.09.143","volume":"320","author":"CN Epperson","year":"2023","unstructured":"Epperson CN, Rubinow DR, Meltzer-Brody S, Deligiannidis KM, Riesenberg R, Krystal AD, et al. Effect of brexanolone on depressive symptoms, anxiety, and insomnia in women with postpartum depression: pooled analyses from 3 double-blind, randomized, placebo-controlled clinical trials in the HUMMINGBIRD clinical program. J Affect Disord. 2023;320:353\u20139.","journal-title":"J Affect Disord"},{"key":"3728_CR164","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","volume":"392","author":"S Meltzer-Brody","year":"2018","unstructured":"Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392:1058\u201370.","journal-title":"Lancet"},{"key":"3728_CR165","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","volume":"78","author":"KM Deligiannidis","year":"2021","unstructured":"Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, Doherty J, Jonas J, Li S, et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry. 2021;78:951\u20139.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR166","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1056\/NEJMoa1815981","volume":"381","author":"H Gunduz-Bruce","year":"2019","unstructured":"Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381:903\u201311.","journal-title":"N Engl J Med"},{"key":"3728_CR167","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","volume":"180","author":"KM Deligiannidis","year":"2023","unstructured":"Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, et al. Zuranolone for the treatment of postpartum depression. Am J Psychiatry. 2023;180:668\u201375.","journal-title":"Am J Psychiatry"},{"key":"3728_CR168","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrendo.2013.31","volume":"9","author":"RD Brinton","year":"2013","unstructured":"Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol. 2013;9:241\u201350.","journal-title":"Nat Rev Endocrinol"},{"key":"3728_CR169","doi-asserted-by":"crossref","first-page":"106169","DOI":"10.1016\/j.nbd.2023.106169","volume":"183","author":"S Luchetti","year":"2023","unstructured":"Luchetti S, Liere P, Pianos A, Verwer RWH, Sluiter A, Huitinga I, et al. Disease stage-dependent changes in brain levels and neuroprotective effects of neuroactive steroids in Parkinson\u2019s disease. Neurobiol Dis. 2023;183:106169.","journal-title":"Neurobiol Dis"},{"key":"3728_CR170","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657\u201373.","journal-title":"Nat Rev Immunol"},{"key":"3728_CR171","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17:157\u201372.","journal-title":"Nat Rev Neurol"},{"key":"3728_CR172","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA\u2010DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology. 1988;38:1285\u20131285.","journal-title":"Neurology"},{"key":"3728_CR173","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2009.05.005","volume":"16","author":"AL Bartels","year":"2010","unstructured":"Bartels AL, Willemsen ATM, Doorduin J, de Vries EFJ, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson\u2019s disease? Parkinsonism Relat Disord. 2010;16:57\u201359.","journal-title":"Parkinsonism Relat Disord"},{"key":"3728_CR174","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/brain\/awad322","volume":"147","author":"A Kouli","year":"2024","unstructured":"Kouli A, Spindler LRB, Fryer TD, Hong YT, Malpetti M, Aigbirhio FI, et al. Neuroinflammation is linked to dementia risk in Parkinson\u2019s disease. Brain. 2024;147:923\u201335.","journal-title":"Brain"},{"key":"3728_CR175","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"X-Y Qin","year":"2016","unstructured":"Qin X-Y, Zhang S-P, Cao C, Loh YP, Cheng Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 2016;73:1316\u201324.","journal-title":"JAMA Neurol"},{"key":"3728_CR176","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JPD-140410","volume":"4","author":"CJ Barnum","year":"2014","unstructured":"Barnum CJ, Chen X, Chung J, Chang J, Williams M, Grigoryan N, et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro\u00ae1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J Parkinsons Dis. 2014;4:349\u201360.","journal-title":"J Parkinsons Dis"},{"key":"3728_CR177","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 2018;75:939\u201346.","journal-title":"JAMA Neurol"},{"key":"3728_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30487-6","volume":"8","author":"A Ng","year":"2018","unstructured":"Ng A, Tam WW, Zhang MW, Ho CS, Husain SF, McIntyre RS, et al. IL-1\u03b2, IL-6, TNF- \u03b1 and CRP in elderly patients with depression or Alzheimer\u2019s disease: systematic review and meta-analysis. Sci Rep. 2018;8:12050.","journal-title":"Sci Rep"},{"key":"3728_CR179","doi-asserted-by":"crossref","first-page":"100992","DOI":"10.1016\/j.eclinm.2021.100992","volume":"38","author":"Z Ye","year":"2021","unstructured":"Ye Z, Kappelmann N, Moser S, Smith GD, Burgess S, Jones PB, et al. Role of inflammation in depression and anxiety: tests for disorder specificity, linearity and potential causality of association in the UK Biobank. EClinicalMedicine. 2021;38:100992.","journal-title":"EClinicalMedicine"},{"key":"3728_CR180","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1017\/S0033291719001454","volume":"49","author":"EF Osimo","year":"2019","unstructured":"Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49:1958\u201370.","journal-title":"Psychol Med"},{"key":"3728_CR181","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biopsych.2008.08.009","volume":"65","author":"FE Lotrich","year":"2009","unstructured":"Lotrich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry. 2009;65:344\u20138.","journal-title":"Biol Psychiatry"},{"key":"3728_CR182","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamapsychiatry.2020.3436","volume":"78","author":"N Kappelmann","year":"2021","unstructured":"Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S, et al. Dissecting the association between inflammation, metabolic dysregulation, and specific depressive symptoms: a genetic correlation and 2-sample mendelian randomization study. JAMA Psychiatry. 2021;78:161\u201370.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR183","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1007\/s10072-022-06363-7","volume":"43","author":"LG Ramanzini","year":"2022","unstructured":"Ramanzini LG, Camargo LFM, Silveira JOF, Bochi GV. Inflammatory markers and depression in Parkinson\u2019s disease: a systematic review. Neurol Sci. 2022;43:6707\u201317.","journal-title":"Neurol Sci"},{"key":"3728_CR184","doi-asserted-by":"crossref","first-page":"e2345175","DOI":"10.1001\/jamanetworkopen.2023.45175","volume":"6","author":"C Schaffer Aguzzoli","year":"2023","unstructured":"Schaffer Aguzzoli C, Ferreira PCL, Povala G, Ferrari-Souza JP, Bellaver B, Soares Katz C, et al. Neuropsychiatric symptoms and microglial activation in patients with Alzheimer disease. JAMA Netw Open. 2023;6:e2345175.","journal-title":"JAMA Netw Open"},{"key":"3728_CR185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/jnnp-2019-320912","volume":"91","author":"S Bai","year":"2020","unstructured":"Bai S, Guo W, Feng Y, Deng H, Li G, Nie H, et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91:21\u201332.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3728_CR186","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2215-0366(20)30138-3","volume":"7","author":"MI Husain","year":"2020","unstructured":"Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020;7:515\u201327.","journal-title":"Lancet Psychiatry"},{"key":"3728_CR187","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/jamapsychiatry.2020.1214","volume":"77","author":"M Berk","year":"2020","unstructured":"Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, et al. Effect of aspirin vs placebo on the prevention of depression in older people: a randomized clinical trial. JAMA Psychiatry. 2020;77:1012\u201320.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR188","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2020","unstructured":"Howard R, Zubko O, Bradley R, Harper E, Pank L, O\u2019Brien J, et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease. JAMA Neurol. 2020;77:164\u201374.","journal-title":"JAMA Neurol"},{"key":"3728_CR189","doi-asserted-by":"crossref","first-page":"e2230367","DOI":"10.1001\/jamanetworkopen.2022.30367","volume":"5","author":"J Hellmann-Regen","year":"2022","unstructured":"Hellmann-Regen J, Clemens V, Gr\u00f6zinger M, Kornhuber J, Reif A, Prvulovic D, et al. Effect of minocycline on depressive symptoms in patients with treatment-resistant depression: a randomized clinical trial. JAMA Netw Open. 2022;5:e2230367.","journal-title":"JAMA Netw Open"},{"key":"3728_CR190","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/mp.2016.167","volume":"23","author":"N Kappelmann","year":"2018","unstructured":"Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23:335\u201343.","journal-title":"Mol Psychiatry"},{"key":"3728_CR191","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31\u201341.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR192","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapsychiatry.2019.0779","volume":"76","author":"RS McIntyre","year":"2019","unstructured":"McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I\/II depression: a randomized clinical trial. JAMA Psychiatry. 2019;76:783\u201390.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR193","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","volume":"84","author":"J Butchart","year":"2015","unstructured":"Butchart J, Brook L, Hopkins V, Teeling J, P\u00fcntener U, Culliford D, et al. Etanercept in Alzheimer disease. Neurology. 2015;84:2161\u20138.","journal-title":"Neurology"},{"key":"3728_CR194","doi-asserted-by":"crossref","first-page":"e025333","DOI":"10.1136\/bmjopen-2018-025333","volume":"8","author":"GM Khandaker","year":"2018","unstructured":"Khandaker GM, Oltean BP, Kaser M, Dibben CRM, Ramana R, Jadon DR, et al. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJ Open. 2018;8:e025333.","journal-title":"BMJ Open"},{"key":"3728_CR195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jad.2023.02.129","volume":"330","author":"Y Du","year":"2023","unstructured":"Du Y, Yu J, Liu M, Qiu Q, Fang Y, Zhao L, et al. The relationship between depressive symptoms and cognitive function in Alzheimer\u2019s disease: the mediating effect of amygdala functional connectivity and radiomic features. J Affect Disord. 2023;330:101\u20139.","journal-title":"J Affect Disord"},{"key":"3728_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02127-y","volume":"7","author":"L Wei","year":"2017","unstructured":"Wei L, Hu X, Zhu Y, Yuan Y, Liu W, Chen H. Aberrant intra- and internetwork functional connectivity in depressed Parkinson\u2019s disease. Sci Rep. 2017;7:2568.","journal-title":"Sci Rep"},{"key":"3728_CR197","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jad.2018.10.364","volume":"245","author":"H Zhang","year":"2019","unstructured":"Zhang H, Qiu Y, Luo Y, Xu P, Li Z, Zhu W, et al. The relationship of anxious and depressive symptoms in Parkinson\u2019s disease with voxel-based neuroanatomical and functional connectivity measures. J Affect Disord. 2019;245:580\u20138.","journal-title":"J Affect Disord"},{"key":"3728_CR198","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(03)12705-5","volume":"361","author":"UK ECT Review Group","year":"2003","unstructured":"UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799\u2013808.","journal-title":"Lancet"},{"key":"3728_CR199","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mds.28335","volume":"36","author":"A Takamiya","year":"2021","unstructured":"Takamiya A, Seki M, Kudo S, Yoshizaki T, Nakahara J, Mimura M, et al. Electroconvulsive therapy for Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2021;36:50\u201358.","journal-title":"Mov Disord"},{"key":"3728_CR200","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1017\/S104161022300039X","volume":"36","author":"AK Bachu","year":"2024","unstructured":"Bachu AK, Kotapati VP, Kainth T, Patel R, Youssef NA, Tampi RR. Electroconvulsive therapy in individuals with dementia\/major NCD presenting with behavioral symptoms: a systematic review. Int Psychogeriatr. 2024;36:864\u201379.","journal-title":"Int Psychogeriatr"},{"key":"3728_CR201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1139\/jpn.0719","volume":"32","author":"EM Strome","year":"2007","unstructured":"Strome EM, Zis AP, Doudet DJ. Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci. 2007;32:193\u2013202.","journal-title":"J Psychiatry Neurosci"},{"key":"3728_CR202","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02251228","volume":"10","author":"PA Fall","year":"1995","unstructured":"Fall PA, Ekman R, Gran\u00e9rus AK, Thorell LH, W\u00e5linder J. ECT in Parkinson\u2019s disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm Park Dis Dement Sect. 1995;10:129\u201340.","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"3728_CR203","first-page":"222","volume":"7","author":"IM Zervas","year":"1991","unstructured":"Zervas IM, Fink M. ECT for refractory Parkinson\u2019s disease. Convuls Ther. 1991;7:222\u20133.","journal-title":"Convuls Ther"},{"key":"3728_CR204","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jagp.2016.02.053","volume":"24","author":"S Kumar","year":"2016","unstructured":"Kumar S, Mulsant BH, Liu AY, Blumberger DM, Daskalakis ZJ, Rajji TK. Systematic review of cognitive effects of electroconvulsive therapy in late-life depression. Am J Geriatr Psychiatry. 2016;24:547\u201365.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3728_CR205","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1176\/appi.ps.202000387","volume":"72","author":"ST Wilkinson","year":"2021","unstructured":"Wilkinson ST, Kitay BM, Harper A, Rhee TG, Sint K, Ghosh A, et al. Barriers to the implementation of electroconvulsive therapy (ECT): results from a nationwide survey of ECT practitioners. Psychiatr Serv. 2021;72:752\u20137.","journal-title":"Psychiatr Serv"},{"key":"3728_CR206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/00207454.2018.1495632","volume":"130","author":"W Hai-jiao","year":"2020","unstructured":"Hai-jiao W, Ge T, Li-na Z, Deng C, Da X, Shan-Shan C, et al. The efficacy of repetitive transcranial magnetic stimulation for Parkinson disease patients with depression. Int J Neurosci. 2020;130:19\u201327.","journal-title":"Int J Neurosci"},{"key":"3728_CR207","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fpsyt.2018.00413","volume":"9","author":"X Cao","year":"2018","unstructured":"Cao X, Deng C, Su X, Guo Y. Response and remission rates following high-frequency vs. low-frequency repetitive transcranial magnetic stimulation (rTMS) over right DLPFC for treating major depressive disorder (MDD): a meta-analysis of randomized, double-blind trials. Front Psychiatry. 2018;9:413.","journal-title":"Front Psychiatry"},{"key":"3728_CR208","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/gerona\/glab235","volume":"77","author":"L Valiengo","year":"2022","unstructured":"Valiengo L, Maia A, Cotovio G, Gordon PC, Brunoni AR, Forlenza OV, et al. Repetitive transcranial magnetic stimulation for major depressive disorder in older adults: systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. 2022;77:851\u201360.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3728_CR209","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4088\/JCP.10r06531","volume":"72","author":"E Tedeschini","year":"2011","unstructured":"Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660\u20138.","journal-title":"J Clin Psychiatry"},{"key":"3728_CR210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1176\/appi.ajp.2021.20101429","volume":"179","author":"EJ Cole","year":"2022","unstructured":"Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022;179:132\u201341.","journal-title":"Am J Psychiatry"},{"key":"3728_CR211","doi-asserted-by":"crossref","first-page":"101589","DOI":"10.1016\/j.eclinm.2022.101589","volume":"52","author":"W Zhang","year":"2022","unstructured":"Zhang W, Deng B, Xie F, Zhou H, Guo J-F, Jiang H, et al. Efficacy of repetitive transcranial magnetic stimulation in Parkinson\u2019s disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2022;52:101589.","journal-title":"EClinicalMedicine"},{"key":"3728_CR212","first-page":"S77","volume":"43","author":"JH Ma","year":"2023","unstructured":"Ma JH, Dong C, Qiao HW, Barret O, Tamagnan GD, Mao W, et al. Striatal and extrastriatal monoaminergic disruption in progressive supranuclear palsy: a 18F-FP-DTBZ PET\/CT study. J Cereb Blood Flow Metab. 2023;43:S77\u2013S77.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3728_CR213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brs.2012.02.005","volume":"6","author":"Z-D Deng","year":"2013","unstructured":"Deng Z-D, Lisanby SH, Peterchev AV. Electric field depth\u2013focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimul. 2013;6:1\u201313.","journal-title":"Brain Stimul"},{"key":"3728_CR214","doi-asserted-by":"crossref","first-page":"109836","DOI":"10.1016\/j.pnpbp.2019.109836","volume":"99","author":"AH Moffa","year":"2020","unstructured":"Moffa AH, Martin D, Alonzo A, Bennabi D, Blumberger DM, Bense\u00f1or IM, et al. Efficacy and acceptability of transcranial direct current stimulation (tDCS) for major depressive disorder: an individual patient data meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109836.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3728_CR215","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41591-024-03305-y","volume":"31","author":"RD Woodham","year":"2025","unstructured":"Woodham RD, Selvaraj S, Lajmi N, Hobday H, Sheehan G, Ghazi-Noori A-R, et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med. 2025;31:87\u201395.","journal-title":"Nat Med"},{"key":"3728_CR216","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/jamapsychiatry.2024.3241","volume":"82","author":"TK Rajji","year":"2025","unstructured":"Rajji TK, Bowie CR, Herrmann N, Pollock BG, Lanct\u00f4t KL, Kumar S, et al. Slowing cognitive decline in major depressive disorder and mild cognitive impairment: a randomized clinical trial. JAMA Psychiatry. 2025;82:12\u201321.","journal-title":"JAMA Psychiatry"},{"key":"3728_CR217","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41380-022-01444-7","volume":"27","author":"A Majdi","year":"2022","unstructured":"Majdi A, van Boekholdt L, Sadigh-Eteghad S, Mc Laughlin M. A systematic review and meta-analysis of transcranial direct-current stimulation effects on cognitive function in patients with Alzheimer\u2019s disease. Mol Psychiatry. 2022;27:2000\u20139.","journal-title":"Mol Psychiatry"},{"key":"3728_CR218","doi-asserted-by":"crossref","first-page":"746797","DOI":"10.3389\/fnagi.2021.746797","volume":"13","author":"X Liu","year":"2021","unstructured":"Liu X, Liu H, Liu Z, Rao J, Wang J, Wang P, et al. Transcranial direct current stimulation for Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2021;13:746797.","journal-title":"Front Aging Neurosci"},{"key":"3728_CR219","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","volume":"17","author":"Y Meng","year":"2021","unstructured":"Meng Y, Hynynen K, Lipsman N. Applications of focused ultrasound in the brain: from thermoablation to drug delivery. Nat Rev Neurol. 2021;17:7\u201322.","journal-title":"Nat Rev Neurol"},{"key":"3728_CR220","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1056\/NEJMoa2016311","volume":"383","author":"R Mart\u00ednez-Fern\u00e1ndez","year":"2020","unstructured":"Mart\u00ednez-Fern\u00e1ndez R, M\u00e1\u00f1ez-Mir\u00f3 JU, Rodr\u00edguez-Rojas R, del \u00c1lamo M, Shah BB, Hern\u00e1ndez-Fern\u00e1ndez F, et al. Randomized trial of focused ultrasound subthalamotomy for Parkinson\u2019s disease. N Engl J Med. 2020;383:2501\u201313.","journal-title":"N Engl J Med"},{"key":"3728_CR221","doi-asserted-by":"crossref","first-page":"eabg7700","DOI":"10.1126\/sciadv.abg7700","volume":"7","author":"D Folloni","year":"2021","unstructured":"Folloni D, Fouragnan E, Wittmann MK, Roumazeilles L, Tankelevitch L, Verhagen L, et al. Ultrasound modulation of macaque prefrontal cortex selectively alters credit assignment\u2013related activity and behavior. Sci Adv. 2021;7:eabg7700.","journal-title":"Sci Adv"},{"key":"3728_CR222","doi-asserted-by":"crossref","unstructured":"Olaitan GO, Ganesana M, Lynch WJ, Legon W, Venton BJ Focused ultrasound modulates dopamine in a mesolimbic reward circuit. J Neurochem. 2025;169:e70001.","DOI":"10.1111\/jnc.70001"},{"key":"3728_CR223","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.brs.2022.01.014","volume":"15","author":"F Munoz","year":"2022","unstructured":"Munoz F, Meaney A, Gross A, Liu K, Pouliopoulos AN, Liu D, et al. Long term study of motivational and cognitive effects of low-intensity focused ultrasound neuromodulation in the dorsal striatum of nonhuman primates. Brain Stimul. 2022;15:360\u201372.","journal-title":"Brain Stimul"},{"key":"3728_CR224","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65080-9","volume":"16","author":"SN Yaakub","year":"2025","unstructured":"Yaakub SN, Eraifej J, Bault N, Lojkiewiez M, Bellec E, Roberts J, et al. Non-invasive ultrasonic neuromodulation of the human nucleus accumbens impacts reward sensitivity. Nat Commun. 2025;16:10192.","journal-title":"Nat Commun"},{"key":"3728_CR225","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.biopsych.2024.09.029","volume":"97","author":"TS Riis","year":"2025","unstructured":"Riis TS, Feldman DA, Kwon SS, Vonesh LC, Koppelmans V, Brown JR, et al. Noninvasive modulation of the subcallosal cingulate and depression with focused ultrasonic waves. Biol Psychiatry. 2025;97:825\u201334.","journal-title":"Biol Psychiatry"},{"key":"3728_CR226","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.parkreldis.2006.12.013","volume":"13","author":"L Morgante","year":"2007","unstructured":"Morgante L, Morgante F, Moro E, Epifanio A, Girlanda P, Ragonese P, et al. How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord. 2007;13:528\u201331.","journal-title":"Parkinsonism Relat Disord"},{"key":"3728_CR227","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2215-0366(17)30371-1","volume":"4","author":"PE Holtzheimer","year":"2017","unstructured":"Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA, McClintock S, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry. 2017;4:839\u201349.","journal-title":"Lancet Psychiatry"},{"key":"3728_CR228","doi-asserted-by":"crossref","first-page":"1100609","DOI":"10.3389\/fpsyt.2023.1100609","volume":"14","author":"M Sobstyl","year":"2023","unstructured":"Sobstyl M, Prokopienko M, Pietras T. The ventral capsule and ventral striatum\u2014stereotactic targets for the management of treatment-resistant depression. A systematic literature review. Front Psychiatry. 2023;14:1100609.","journal-title":"Front Psychiatry"},{"key":"3728_CR229","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41591-021-01480-w","volume":"27","author":"KW Scangos","year":"2021","unstructured":"Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP, Zamanian H, et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. Nat Med. 2021;27:1696\u20131700.","journal-title":"Nat Med"},{"key":"3728_CR230","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.biopsych.2019.01.017","volume":"85","author":"H Tyagi","year":"2019","unstructured":"Tyagi H, Apergis-Schoute AM, Akram H, Foltynie T, Limousin P, Drummond LM, et al. A randomized trial directly comparing ventral capsule and anteromedial subthalamic nucleus stimulation in obsessive-compulsive disorder: clinical and imaging evidence for dissociable effects. Biol Psychiatry. 2019;85:726\u201334.","journal-title":"Biol Psychiatry"},{"key":"3728_CR231","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/brainsci12070933","volume":"12","author":"T Xu","year":"2022","unstructured":"Xu T, Gao Y, Li B, Jiang J, Guo H, Liu X, et al. The efficacy and safety of deep brain stimulation of combined anterior limb of internal capsule and nucleus accumbens (ALIC\/NAcc-DBS) for treatment-refractory obsessive-compulsive disorder: protocol of a multicenter, randomized, and double-blinded study. Brain Sci. 2022;12:933.","journal-title":"Brain Sci"},{"key":"3728_CR232","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.bp.114.148403","volume":"209","author":"RM van der Linde","year":"2016","unstructured":"van der Linde RM, Dening T, Stephan BCM, Prina AM, Evans E, Brayne C. Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. Br J Psychiatry. 2016;209:366\u201377.","journal-title":"Br J Psychiatry"},{"key":"3728_CR233","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10928-015-9457-6","volume":"43","author":"A Akil","year":"2016","unstructured":"Akil A, Bies RR, Pollock BG, Avramopoulos D, Devanand DP, Mintzer JE, et al. A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer\u2019s disease patients with agitation. J Pharmacokinet Pharmacodyn. 2016;43:99\u2013109.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3728_CR234","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1007\/s00213-016-4379-6","volume":"233","author":"S Reeves","year":"2016","unstructured":"Reeves S, Bertrand J, D\u2019Antonio F, McLachlan E, Nair A, Brownings S, et al. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer\u2019s disease. Psychopharmacology. 2016;233:3371\u201381.","journal-title":"Psychopharmacology"},{"key":"3728_CR235","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/brain\/aww359","volume":"140","author":"S Reeves","year":"2017","unstructured":"Reeves S, McLachlan E, Bertrand J, D\u2019Antonio F, Brownings S, Nair A, et al. Therapeutic window of dopamine D2\/3 receptor occupancy to treat psychosis in Alzheimer\u2019s disease. Brain. 2017;140:1117\u201327.","journal-title":"Brain"},{"key":"3728_CR236","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2024.12.004","volume":"98","author":"RA McCutcheon","year":"2025","unstructured":"McCutcheon RA, Cowen P, Nour MM, Pillinger T. Psychotropic taxonomies: constructing a therapeutic framework for psychiatry. Biol Psychiatry. 2025;98:446\u201354.","journal-title":"Biol Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03728-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:57:36Z","timestamp":1792011456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03728-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":236,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3728"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03728-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PG has attended a Janssen New Zealand advisory board, and is named on a patent for a controlled release ketamine tablet developed by Douglas Pharmaceuticals. In the past 36 months. A.Y receives fees for lectures and serves on advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema Pharma, Compass, AstraZeneca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, LivaNova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, and Neurocentrx. He is the principal investigator in the Restore-Life VNS registry study funded by LivaNova and \u201cESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.\u201d He is the principal investigator for \u201cThe Effects of Psilocybin on Cognitive Function in Healthy Participants\u201d and \u201cThe Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)\u201d studies, including \u201cA Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20\u2009mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy,\u201d \u201cAn Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD),\u201d \u201cA Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10\u2009mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy,\u201d and \u201cA Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR.\u201d AHY is also the UK Chief Investigator for Compass COMP006 and COMP007 studies and Novartis MDD study MIJ821A12201.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}